AU2010288546B2 - Bifidobacterium longum and functional GI disorders - Google Patents

Bifidobacterium longum and functional GI disorders Download PDF

Info

Publication number
AU2010288546B2
AU2010288546B2 AU2010288546A AU2010288546A AU2010288546B2 AU 2010288546 B2 AU2010288546 B2 AU 2010288546B2 AU 2010288546 A AU2010288546 A AU 2010288546A AU 2010288546 A AU2010288546 A AU 2010288546A AU 2010288546 B2 AU2010288546 B2 AU 2010288546B2
Authority
AU
Australia
Prior art keywords
composition
bifidobacterium longum
accordance
functional
atcc baa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010288546A
Other languages
English (en)
Other versions
AU2010288546A1 (en
Inventor
Premysl Bercik
Gabriela Bergonzelli De Gonda
Stephen Michael Collins
Peter Mclean
Elena Verdu De Bercik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
Original Assignee
Societe des Produits Nestle SA
Nestle SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41508246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2010288546(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Societe des Produits Nestle SA, Nestle SA filed Critical Societe des Produits Nestle SA
Publication of AU2010288546A1 publication Critical patent/AU2010288546A1/en
Application granted granted Critical
Publication of AU2010288546B2 publication Critical patent/AU2010288546B2/en
Assigned to Société des Produits Nestlé S.A. reassignment Société des Produits Nestlé S.A. Request for Assignment Assignors: NESTEC S.A.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2010288546A 2009-08-25 2010-08-24 Bifidobacterium longum and functional GI disorders Active AU2010288546B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09168590.9 2009-08-25
EP09168590.9A EP2289527B1 (en) 2009-08-25 2009-08-25 Bifidobacterium longum and functional GI disorders
PCT/EP2010/062320 WO2011023689A1 (en) 2009-08-25 2010-08-24 Bifidobacterium longum and functional gi disorders

Publications (2)

Publication Number Publication Date
AU2010288546A1 AU2010288546A1 (en) 2012-03-22
AU2010288546B2 true AU2010288546B2 (en) 2015-08-20

Family

ID=41508246

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010288546A Active AU2010288546B2 (en) 2009-08-25 2010-08-24 Bifidobacterium longum and functional GI disorders

Country Status (17)

Country Link
US (3) US10028981B2 (enExample)
EP (2) EP2289527B1 (enExample)
JP (4) JP2013503130A (enExample)
CN (2) CN106072658A (enExample)
AU (1) AU2010288546B2 (enExample)
BR (1) BR112012004046B1 (enExample)
CA (1) CA2772163C (enExample)
CL (1) CL2012000487A1 (enExample)
DK (1) DK2289527T3 (enExample)
ES (1) ES2664828T3 (enExample)
IN (1) IN2012DN01638A (enExample)
MX (1) MX2012002402A (enExample)
RU (1) RU2012111253A (enExample)
SG (1) SG178499A1 (enExample)
TR (1) TR201807143T4 (enExample)
WO (1) WO2011023689A1 (enExample)
ZA (1) ZA201202155B (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768030C2 (ru) * 2017-02-28 2022-03-23 Элиментари Хелт Лимитед Bifidobacterium longum, способный благоприятно модулировать иммунный ответ на респираторную вирусную инфекцию
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
IN2014DN07752A (enExample) 2012-02-29 2015-05-15 Ethicon Endo Surgery Inc
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
SG11201703395PA (en) 2014-10-31 2017-05-30 Whole Biome Inc Methods and compositions relating to microbial treatment and diagnosis of disorders
WO2016183535A1 (en) 2015-05-14 2016-11-17 University Of Puerto Rico Methods for restoring microbiota of newborns
EP3307290B2 (en) 2015-06-11 2025-03-05 Société des Produits Nestlé S.A. Dietary supplement
MX2018001851A (es) * 2015-08-31 2018-05-17 Nestec Sa Metodos y composiciones que usan bifidobacterium longum para tratar o prevenir sintomas depresivos.
MX2018001849A (es) * 2015-08-31 2018-05-16 Nestec Sa Metodos y composiciones que usan bifidobacterium longum para modular la reactividad emocional y tratar o prevenir perturbaciones subclinicas del estado de animo.
WO2017037105A1 (en) * 2015-08-31 2017-03-09 Nestec S.A. Methods and compositions using bifidobacterium longum to optimize breastfeeding
EP3368047B1 (en) 2015-10-28 2023-04-26 Glycom A/S Synthetic composition and method for modulating emotion and mood disorders
EP3368046B1 (en) * 2015-10-28 2022-07-27 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
US11564667B2 (en) 2015-12-28 2023-01-31 New York University Device and method of restoring microbiota of newborns
JP6353478B2 (ja) * 2016-03-28 2018-07-04 日清食品ホールディングス株式会社 セロトニン分泌促進能力を有するビフィズス菌
CN107050062A (zh) * 2016-11-08 2017-08-18 江西益盟科技有限公司 治疗便秘的乳酸菌组合物及其制备方法
CN106579414A (zh) * 2016-12-26 2017-04-26 北京康比特体育科技股份有限公司 一种缓解运动性腹泻的组合物
AU2018263770A1 (en) * 2017-05-05 2019-10-03 Societe Des Produits Nestle S.A. Treatment of infant colic
JP2020532515A (ja) 2017-08-30 2020-11-12 ペンデュラム セラピューティクス， インコーポレイテッド マイクロバイオーム関連障害の処置のための方法および組成物
US20190298783A1 (en) 2018-03-28 2019-10-03 Morinaga Milk Industry Co., Ltd. Composition for relieving stress, pharmaceutical composition and food and drink composition and method for relieving stress using the composition for relieving stress
EP3823651A4 (en) 2018-07-19 2022-04-27 Pendulum Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MICROBIAL TRANSPLANTATION
AU2020299976B2 (en) * 2019-07-01 2025-08-21 Société des Produits Nestlé S.A. Serpin production
JP2021014422A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 便性改善剤
JP2021014421A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 Ｑｏｌ改善剤
CN111187734A (zh) * 2019-12-25 2020-05-22 生合生物科技（扬州）有限公司 长双歧杆菌bl986、由其制备的冻干粉及冻干粉的应用
WO2021233923A1 (en) * 2020-05-20 2021-11-25 Société des Produits Nestlé S.A. Improvement of insoluble fibre fermentability and short chain fatty acid production by bifidobacterium longum

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974735A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Reduction of risk of diarrhoea

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
DE10008279A1 (de) * 2000-02-23 2001-08-30 Meggle Gmbh Milchzucker enthaltende Zusammensetzung
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
US7033629B2 (en) * 2001-08-31 2006-04-25 Nutricopia Inc. Nutritional frozen dessert and methods of manufacture
EP1384483A1 (en) 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
JP2004262773A (ja) * 2003-02-17 2004-09-24 Ryoshoku Kenkyukai 免疫機能改善を目的としたビフィズス菌製剤
US20040265279A1 (en) 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
NZ544726A (en) * 2003-06-23 2009-05-31 Nestec Sa Infant or follow-on formula
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
US8134942B2 (en) * 2005-08-24 2012-03-13 Avaak, Inc. Communication protocol for low-power network applications and a network of sensors using the same
DE602006017423D1 (de) * 2005-11-14 2010-11-18 Unilever Nv Essbares produkt, das ginseng-polysaccharide und gesunde bakterien enthält
JP2007169200A (ja) * 2005-12-21 2007-07-05 Morinaga Milk Ind Co Ltd インフルエンザ感染予防のための医薬及び飲食品
PT1986669E (pt) * 2006-02-15 2012-05-15 Nestec Sa Utilização de bifidobacterium longum para a prevenção e tratamento de inflamação
AU2007222598B2 (en) 2006-03-07 2013-01-10 Société des Produits Nestlé S.A. Synbiotic mixture
EP1961308A1 (en) * 2007-02-21 2008-08-27 Nestec S.A. Nutritionally balanced frozen dessert
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
CA2707656C (en) * 2007-12-06 2018-05-22 Arla Foods Amba Probiotic bacteria and regulation of fat storage
WO2009079544A1 (en) * 2007-12-17 2009-06-25 University Of Florida Research Foundation, Inc. Materials and methods for treatment of pathological ocular vascular proliferation
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
TR201807143T4 (tr) 2009-08-25 2018-06-21 Nestec Sa Bifidobacterium longum ve fonksiyonel gastrointestinal bozukluklar.
KR102760825B1 (ko) * 2018-01-29 2025-02-03 프리시젼바이오틱스 그룹 리미티드 과민성 대장 증후군의 예방 및 치료를 위한 조합 생성물

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1974735A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Reduction of risk of diarrhoea

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2768030C2 (ru) * 2017-02-28 2022-03-23 Элиментари Хелт Лимитед Bifidobacterium longum, способный благоприятно модулировать иммунный ответ на респираторную вирусную инфекцию
US11529381B2 (en) 2017-02-28 2022-12-20 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection

Also Published As

Publication number Publication date
CA2772163C (en) 2017-11-07
US20220280576A1 (en) 2022-09-08
EP2470188A1 (en) 2012-07-04
SG178499A1 (en) 2012-04-27
JP7096652B6 (ja) 2022-08-01
IN2012DN01638A (enExample) 2015-06-05
ES2664828T3 (es) 2018-04-23
BR112012004046B1 (pt) 2021-02-17
CA2772163A1 (en) 2011-03-03
CN106072658A (zh) 2016-11-09
TR201807143T4 (tr) 2018-06-21
CL2012000487A1 (es) 2012-08-31
US11957720B2 (en) 2024-04-16
JP2016074682A (ja) 2016-05-12
JP2020183385A (ja) 2020-11-12
DK2289527T3 (en) 2018-04-23
WO2011023689A1 (en) 2011-03-03
EP2289527A1 (en) 2011-03-02
AU2010288546A1 (en) 2012-03-22
US20190134104A1 (en) 2019-05-09
US11452745B2 (en) 2022-09-27
US10028981B2 (en) 2018-07-24
JP2013503130A (ja) 2013-01-31
CN102573863A (zh) 2012-07-11
ZA201202155B (en) 2014-09-25
JP2018048112A (ja) 2018-03-29
JP7096652B2 (ja) 2022-07-06
RU2012111253A (ru) 2013-10-10
EP2289527B1 (en) 2018-02-21
BR112012004046A2 (pt) 2017-05-30
MX2012002402A (es) 2012-04-02
US20120230956A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
US11957720B2 (en) Bifidobacterium longum and functional GI disorders
DK3072398T3 (en) BIFIDOBACTERIUM LONGUM AND HIPPOCAMPAL BDNF EXPRESSION
AU2010247467A1 (en) Non-replicating micro-organisms and their immune boosting effect
CN105142654A (zh) 肠小型生物群中的毛螺菌科和与体重的关联
HK1228677B (en) Bifidobacterium longum and hippocampal bdnf expression
HK1228677A1 (en) Bifidobacterium longum and hippocampal bdnf expression

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: SOCIETE DES PRODUITS NESTLE S.A.

Free format text: FORMER OWNER(S): NESTEC S.A.